Media headlines about MOTIF BIO PLC/S (NASDAQ:MTFB) have been trending positive this week, according to Accern. Accern rates the sentiment of media coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. MOTIF BIO PLC/S earned a news impact score of 0.33 on Accern’s scale. Accern also gave press coverage about the company an impact score of 44.7023256390076 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Here are some of the news stories that may have impacted Accern Sentiment Analysis’s rankings:
- MOTIF BIO PLC/S (MTFB) Given a $32.00 Price Target at HC Wainwright (americanbankingnews.com)
- Motif Bio says two new US patents push exclusivity period over antibiotic out to 2037 (proactiveinvestors.co.uk)
- Motif Bio Announces Notice of Allowance for Two U.S. Iclaprim Patents with Expiration in 2037 (finance.yahoo.com)
- MOTIF BIO PLC/S (MTFB) Receives Consensus Rating of “Hold” from Analysts (americanbankingnews.com)
Shares of NASDAQ:MTFB traded down $0.04 during trading on Friday, reaching $8.10. The stock had a trading volume of 2,300 shares, compared to its average volume of 614. The company has a debt-to-equity ratio of -1.58, a current ratio of 0.96 and a quick ratio of 0.96. The firm has a market capitalization of $120.73 million, a PE ratio of -42.63 and a beta of -0.05. MOTIF BIO PLC/S has a 1-year low of $6.84 and a 1-year high of $13.75.
MOTIF BIO PLC/S Company Profile
Motif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. Its lead product candidate is iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital-acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus, as well as to treat lung infections caused by Staphylococcus aureus in patients with cystic fibrosis.
Recommended Story: Understanding Price to Earnings Ratio (PE)
Receive News & Ratings for MOTIF BIO PLC/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MOTIF BIO PLC/S and related companies with MarketBeat.com's FREE daily email newsletter.